Form 483

Eugia Pharma Specialities Limited Form 483, 2017-04-28

FDA issued a Form 483 to Eugia Pharma Specialities Limited on 2017-04-28 with 21 public-safe observations.

483· Form 483 issuedHuman Drugs21 observations

Eugia Pharma Specialities Limited · Sangareddy, India · Issued April 28, 2017

Overview

  • 21 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

28 Apr 2017
21 CFR 211.100(a)

Changes to Procedures Not Reviewed, Approved

Cited by Saleem A Akhtar, Scott T Ballard

28 Apr 2017
21 CFR 211.100(a)

Changes to Procedures Not Reviewed, Approved

Cited by Saleem A Akhtar, Scott T Ballard

28 Apr 2017
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Saleem A Akhtar, Scott T Ballard

28 Apr 2017
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Saleem A Akhtar, Scott T Ballard

28 Apr 2017
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Saleem A Akhtar, Scott T Ballard

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations3x
21 CFR 211.113(b)Cited across public-safe Form 483 observations3x
21 CFR 211.160(b)Cited across public-safe Form 483 observations3x
21 CFR 211.192Cited across public-safe Form 483 observations3x
21 CFR 211.58Cited across public-safe Form 483 observations3x
21 CFR 211.63Cited across public-safe Form 483 observations3x
21 CFR 211.68(b)Cited across public-safe Form 483 observations3x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 21 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere